Elite Pharmaceuticals Inc (ELTP)

[Couch]

COULD TURN OUT TO BE THE PERFECT STORM
1) The White House has an agenda to curb the epidemic that is prescription drug abuse....
http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdf
Prescription drug abuse is the Nation’s fastest-growing drug problem. While there has been a marked decrease in the use of some illegal drugs like cocaine, data from the National Survey on Drug Use and Health (NSDUH) show that nearly one-third of people aged 12 and over who used drugs for the first time in 2009 began by using a prescription drug non-medically.

2) The House of Representatives recently passed a bill that gives additional funding to the FDA to offset drug shortages....
http://www.reuters.com/article/2012/05/30/us-congress-fda-idUSBRE84T1LQ20120530
The main purpose of the bill is to reauthorize fees from makers of drugs and devices that help speed FDA evaluation of new medical products. These so-called "user fees" could make up nearly half of the FDA's proposed $4.5 billion budget next year, according to a plan from President Barack Obama.
~~As we know Naltrexone is one of those drugs on various drug shortage lists!
http://www.ashp.org/DrugShortages/Current/bulletin.aspx?id=873

3) The Supreme Court upheld the constitutionality of Obama's Health Care Plan....meaning that everyone will be required to have health care. This, though controversial, will unsure that less money will be spent on the poor and indigent population that uses a disproportionate amount of prescription related opioid abuse funds.
http://www.voanews.com/content/breaking-news-us-supreme-court-health-care-decision/1264278.html

***4) The FDA understands the need to develop abuse resistant opioids and has publicly stated it would make it a priority this year!
http://www.genengnews.com/keywordsandtools/print/3/26691/
Addressing Leerink Swann’s Global Healthcare Conference last month, Janet Woodcock, M.D., director of FDA’s Center for Drug Evaluation and Research, included development of abuse-resistant opioids and novel nonopioid pain therapies among the agency’s priorities this year. Dr. Woodcock spoke eight months after the Institute of Medicine issued a “blueprint for action,” calling for increased coordination of government, business, and academic efforts to improve pain prevention, care, education, and research by 2015.

***6) THE KICKER~~~MANAGED CARE WILL GLADL PAY FOR ELI 216
http://www.thci.org/Opioid/jun10docs/Howard_Birnbaum.pdf

Opioid abuse imposes substantial costs on MCOs ? At the patient level, both abusers and their caregivers have substantial excess costs ? At the societal level, opioid abuse costs over $50 billion annually

Two potentially fruitful strategies for addressing opioid abuse are ? Introduction of opioids designed to deter abuse or ease of extraction ? Evidence-based analysis to better identify patients who may be at risk for opioid abuse

***7) THE FDA IS SLOWLY MOVING TOWARDS ABUSE RESISTANT OPIOIDS!!!! COME ON JT LET'S GET MOVING!!!
http://blogs.fda.gov/fdavoice/index.php/2012/04/fdas-commitment-to-reducing-prescription-drug-abuse-and-misuse/
FDA’s Commitment to Reducing Prescription Drug Abuse and Misuse